

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Albrecht
Art Unit	
Examiner Name	
Attorney Docket Number	BJA319A

Sheet 1 of 3

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-	4,992,257	02-12-1991	Bonnett et al	
	US-	5,162,519	11-10-1992	Bonnett et al	
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner
SignatureDate
Considered

9/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Albrecht
		Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	BJA319A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/su K		DASS et al, "Enhanced Anticancer Therapy Mediated by Specialized Liposomes", J. Pharm. Pharmacol. 1997, 972-75 v. 49	
		STORM et al, "Liposomes: quo vadis?", Pharm. Science & Tech. Today, April 1998, 19-31, v. 1, Elsevier Science	
		HARRIS et al, "Effect of Pegylation on Pharmaceuticals", Nature, March 2003, 214-221, v. 1, Nature Pub. Grp.	
		PAPAHADJOPOULOS et al, "Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy", Proc. Natl. Acad. Sci. USA, Dec 1991, 11460-64, v. 88	
		MUGGIA et al, "Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation", J. of Clinical Oncology, March 1997, 987-993, v. 15, no. 3	
		MODY et al, "Pharmaceutical development and medical applications of porphyrin-type macrocycles", Journal of Porphyrins & Phthalocyanines 2000, 362-367, v. 4	
		STERNBERG et al, "Porphyrin-based Photosensitizers for Use in Photodynamic Therapy, Tetrahedron 1998, 4151-4202, v. 54	

Examiner Signature	K	Date Considered	9/04
--------------------	---	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Albrecht
		Art Unit	
		Examiner Name	
Sheet	3	of	3
		Attorney Docket Number	BJA319A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LS		DERYCKE et al, "Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes", Intl. J. of Oncology 2002, 181-187, v. 20	
		WOODLE et al, "Sterically stabilized liposomes" Biochimica et Biophysica Acta 1992, 171-199, v. 1113	
		VAAGE et al, "Therapy of Primary & Metastatic Mouse Mammary Carcinomas with Doxorubicin Encapsulated in Long Circulating Liposomes", Int. J. Cancer 1992, 942-948, v. 51	
		STEWART et al, "Randomized Comparative Trial of Pegylated Liposomal Doxorubicin Versus Bleomycin & Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma", J. of Clinical Oncology, Feb 1998, 683-691, v. 16, no. 2	
		NORTHFELT et al, "Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, & Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma: Results of a Randomized Phase III Clinical Trial", J. of Clinical Oncology, July 1998, 2445-2451, v. 16, no. 7	

Examiner Signature	Kuhn	Date Considered	9/04
--------------------	------	-----------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.